Related to Galapagos Earns Just Over $5M from Merck & Co. for Achieving Milestones in Metabolic and Inflammatory Disease Deals

• Merck & Co. Licenses Portola Phase II Stroke Therapy for $50M Up Front
  
• Addex Gets $500K from Merck & Co. for Reaching Preclinical Milestone
  
• Merck Pays Depomed $10M for Patents to Expand Use of Antidiabetic
  
• Galapagos Receives $3.57M for Reaching Milestone in Osteoporosis Collaboration with Lilly
  
• Covance Takes Over Merck & Co.’s Gene-Expression Lab and Gains $145M Contract
  
• Merck & Co. to Market CSL’s Seasonal Flu Vaccine in the U.S.
  
• Good and Bad News at Idera
  
• Merck & Co. Extends Research Arrangement with Addex for One More Year
  
• GSK Pays Galapagos $9.45M to Broaden Scope of Arthritis Deal
  
• Roche Pays About $8.7M to Partner with Galapagos for COPD Target and Drug Discovery
  
• Merck & Co. Taps Envoy for Target Discovery in Diabetes and Obesity
  
• Merck & Co. Passes Late-Stage Onychomycosis Therapy Back to Anacor
  
• BG Medicine Forges Pact with Merck & Co. to Develop a Molecular Diagnostic for Lipid Disorders
  
• Galapagos and MorphoSys Add Fourth Target to Ongoing Alliance in Bone and Joint Diseases
  
• Merck & Co. Negotiates Co-Promotion Rights to Nycomed’s Oral COPD Therapy in Certain European Countries
  
• Merck Gains Control of Ariad’s Ridaforolimus Program
  
• Merck & Co. Inks Partnership with ElexoPharm Focused on Cardiovascular Diseases
  
• Merck Teams with Adcock Ingram to Market OTC and Rx Products in South Africa
  
• NIH Prolongs Compound-Management Arrangement with Galapagos Until End of 2012
  
• Bristol University Teams Up with Galapagos to Develop Neuropathic Pain Therapy